A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique ...

Researchers have identified key factors that determine the success of leukemia cell therapies, including DLI, in achieving ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in cancer immunotherapy. The team discovered a unique population of immune cells ...

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

The hospital threatened "to get the law involved," his friend said. "You tell me how that’s right for a man that’s fighting ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a ...

The analysis found that less than fifty percent of enrolled patients deceased after the median follow-up period of 13.5 months, indicating a median survival of over 13.5 Months in the trial vs.

Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification – - Based on a Review of ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

The combination of treosulfan and fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation ...